Abstract
The blood-brain barrier (BBB) is a dynamic barrier essential for maintaining the micro-environment of the brain. Although the special anatomical features of the BBB determine its protective role for the central nervous system (CNS) from blood-born neurotoxins, however, the BBB extremely limits the therapeutic efficacy of drugs into the CNS, which greatly hinders the treatment of major brain diseases. This review summarized the unique structures of the BBB, described a variety of in vivo and in vitro experimental methods for determining the transport properties of the BBB, e.g., the permeability of the BBB to water, ions, and solutes including nutrients, therapeutic agents and drug carriers, and presented newly developed mathematical models which quantitatively correlate the anatomical structures of the BBB with its barrier functions. Finally, on the basis of the experimental observations and the quantitative models, several strategies for drug delivery through the BBB were proposed.
Keywords: Drug delivery, in vivo and in vitro blood-brain barrier models, paracellular pathway, permeability of the bloodbrain barrier, transcellualr pathway, transport models.
Current Pharmaceutical Biotechnology
Title:Experimental Methods and Transport Models for Drug Delivery Across the Blood-Brain Barrier
Volume: 13 Issue: 7
Author(s): Bingmei M. Fu
Affiliation:
Keywords: Drug delivery, in vivo and in vitro blood-brain barrier models, paracellular pathway, permeability of the bloodbrain barrier, transcellualr pathway, transport models.
Abstract: The blood-brain barrier (BBB) is a dynamic barrier essential for maintaining the micro-environment of the brain. Although the special anatomical features of the BBB determine its protective role for the central nervous system (CNS) from blood-born neurotoxins, however, the BBB extremely limits the therapeutic efficacy of drugs into the CNS, which greatly hinders the treatment of major brain diseases. This review summarized the unique structures of the BBB, described a variety of in vivo and in vitro experimental methods for determining the transport properties of the BBB, e.g., the permeability of the BBB to water, ions, and solutes including nutrients, therapeutic agents and drug carriers, and presented newly developed mathematical models which quantitatively correlate the anatomical structures of the BBB with its barrier functions. Finally, on the basis of the experimental observations and the quantitative models, several strategies for drug delivery through the BBB were proposed.
Export Options
About this article
Cite this article as:
M. Fu Bingmei, Experimental Methods and Transport Models for Drug Delivery Across the Blood-Brain Barrier, Current Pharmaceutical Biotechnology 2012; 13 (7) . https://dx.doi.org/10.2174/138920112800624409
DOI https://dx.doi.org/10.2174/138920112800624409 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intercellular Genomic (Chromosomal) Variations Resulting in Somatic Mosaicism: Mechanisms and Consequences
Current Genomics Antiplatelet and Antileukocyte Effects of Cardiovascular,Immunomodulatory and Chemotherapeutic Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Current Drug Targets Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Interview: Dr. Muin J. Khoury Discusses the Future of Public Health Genomics and why it Matters for Personalized Medicine and Global Health
Current Pharmacogenomics and Personalized Medicine Inhibition of Tau Aggregation in Cell Models of Tauopathy
Current Alzheimer Research Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Functional Link Between Adenosine and Insulin: A Hypothesis for Fetoplacental Vascular Endothelial Dysfunction in Gestational Diabetes
Current Vascular Pharmacology The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Safer Vectors for Gene Therapy of Primary Immunodeficiencies
Current Gene Therapy Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism A Proteome-Level Computational Biology Insight on Sequence Based Aggregation Propensity Profile of Human Hydrolase Structural Enzymes
Current Biotechnology From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders
Current Pharmaceutical Design Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes
Current Pharmaceutical Design A Newly Synthetized Ferrocenyl Derivative Selectively Induces Apoptosis in ALL Lymphocytes through Mitochondrial Estrogen Receptors
Anti-Cancer Agents in Medicinal Chemistry Medical Expert Systems
Current Bioinformatics